Monthly Archives: May 2017

sphingotec and bestbion dx partner to market predictive biomarkers for guidance of therapy in acute heart failure and septic shock

Hennigsdorf-Berlin/Cologne  – German diagnostics company sphingotec GmbH (Hennigsdorf) and bestbion dx GmbH (Cologne) have signed an agreement to market sphingotec’s innovative sepsis and congestive heart failure test (sphingotest® bio-ADM) and acute kidney function monitoring assay (sphingotest® penKid). Under the agreement, bestbion dx will market both biomarker assays, set to improve therapy monitoring and outcomes in…
Read more

Cookie Preference

Please select an option. You can find more information about the consequences of your choice at Help. Privacy Policy | Imprint

Select an option to continue

Your selection was saved!

More information


To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.

  • Accept all cookies:
    All cookies such as tracking and analytics cookies.
  • Accept first-party cookies only:
    Only cookies from this website.
  • Reject all cookies:
    No cookies except for those necessary for technical reasons are set. Borlabs Cookie already set a necessary cookie.

You can change your cookie setting here anytime: Privacy Policy. Imprint